HomeAI · summaries
Storia in 2 fonti
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer - Natera (NASDAQ:NTRA)
Natera won Japan approval for Signatera in colorectal cancer, paving the way for a commercial launch by 2026.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
benzinga.com
Why Is Natera Stock Gaining Tuesday? - Natera (NASDAQ:NTRA)
Natera (NTRA) stock rallies following a key NCCN guideline update for Signatera. Also, check out the full NTRA stock analysis.
- ·
morningstar.com
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
Signatera™ Receives Regulatory Approval in Japan for Colorectal CancerFirst PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the…
